EMJ Dermatology 13 [Supplement 1] . 2025

In this issue

Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and ARCADIA-2) in adults and adolescents with moderate to-severe atopic dermatitis. This article summarises selected data on nemolizumab’s long-term safety and efficacy in AD up to 56 weeks from oral presentations delivered for the first time at the European Academy of Dermatology and Venereology (EADV) Congress 2024.